Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cogent BiosciencesCOGT -1.24%30 3-1 Month Momentum % is 1.96% as of Jul. 25, 2026. GuruFocus rates COGT with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 1,392 Biotechnology companies, Cogent Biosciences ranks better than 69.54% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-25), Cogent Biosciences's 3-1 Month Momentum % is 1.96%.
The industry rank for Cogent Biosciences's 3-1 Month Momentum % or its related term are showing as below:
COGT's 3-1 Month Momentum % is ranked better than 69.54% of 1392
companies
in the Biotechnology industry
Industry Median: -10.615
vs COGT: 1.96
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Cogent Biosciences 3-1 Month Momentum % Related Terms
COGT vs SRRK, CGON, LGND: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Cogent Biosciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences (COGT) has a 3-1 Month Momentum % of 1.96% as of Jul. 25, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cogent Biosciences and its competitors. According to the industry distribution chart, Cogent Biosciences ranks #424 out of 1392 companies in the Biotechnology industry, placing it in the top 30.5%.
Is Cogent Biosciences' 3-1 Month Momentum % too high?
Cogent Biosciences' current 3-1 Month Momentum % is 1.96%. Based on the distribution chart, Cogent Biosciences ranks #424 out of 1392 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cogent Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' 3-1 Month Momentum % compare to SRRK and CGON?
According to the Biotechnology industry distribution chart, Cogent Biosciences ranks #424 out of 1392 companies for 3-1 Month Momentum %. This puts Cogent Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cogent Biosciences and its competitors. Cogent Biosciences's current 3-1 Month Momentum % is 1.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current 3-1 Month Momentum % of 1.96%. The current 3-1 Month Momentum % is 1.96%. Cogent Biosciences' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current 3-1 Month Momentum % is 1.96% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
30GF Score
Get the complete analysis for COGT
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGT has been successfully added to your 
